SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Discussion surrounding Internet Computer (ICP) is fragmented, with participants debating its long-term potential as decentralized cloud infrastructure against frustration over its prolonged price underperformance and the recent shift in stance from prominent project influencers. While some traders view current price levels as an accumulation opportunity based on ongoing ecosystem developments, others express significant skepticism and label the asset a failed project.

OpenAI

The community discussion is currently fragmented, with primary focus on the potential 2027 IPO timeline, ongoing leadership turnover, and recent security incidents involving model containment and hacking. Traders are debating the long-term viability of the company's high capital expenditure against competitors like Anthropic, while some speculate on potential impacts from government-related ownership proposals and legal challenges.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium is trending primarily due to the announcement of strong financial results, including positive cash flow and significant new offtake agreements, which led to a notable share price increase. Traders are debating the company's operational execution and debt reduction, with some expressing optimism about the stock's future performance following these developments.

Curaleaf Holdings, Inc. operates as a holding company with interest in medical and wellness cannabis operations. It operates through the Domestic Operations and International Operations segments. The company was founded on November 13, 2014 and is headquartered in Stamford, CT.

Curaleaf Holdings Inc

Curaleaf is trending as traders discuss the company's aggressive expansion strategy, including a contested takeover bid for Aurora Cannabis and ongoing international growth efforts. While supporters highlight the company's scale and management, community discourse remains split, with some questioning the impact of dilution and potential overextension compared to peers.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as traders focus on positive clinical data, heavy insider buying from Co-CEO Robert Duggan, and anticipation surrounding upcoming oncology conferences and the November regulatory decision. While some participants discuss the potential for a short squeeze given the significant short interest, others express uncertainty regarding the company's valuation and regulatory path.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is trending as investors monitor the company's progress toward the Q3 2026 resubmission of its Anaphylm New Drug Application, following positive clinical pharmacokinetic and human factors study results. While some traders express optimism regarding the drug's non-invasive portability and competitive differentiation, others remain cautious, citing past regulatory setbacks and potential dilution concerns.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as the community anticipates upcoming regulatory milestones and continued clinical progress for its lead psilocybin-based treatment, COMP360. Traders are actively debating the timing of a potential buyout, the company's competitive position as a first mover in the sector, and the significance of recent engagements with the U.S. Department of Veterans Affairs.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending as traders focus on the company's strong institutional ownership, record revenue growth, and raised guidance, which have fueled speculation about its long-term turnaround potential. Community discussion is dominated by bullish sentiment regarding the upcoming September 16th investor day, with many traders drawing comparisons to other high-growth healthcare stocks.

GitLab, Inc. engages in the intelligent development, security, and operations (DevSecOps) platform for software innovation. It enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab is experiencing a surge in investor interest following strong fiscal quarterly results that beat revenue and earnings estimates, alongside an improved full-year forecast. The community sentiment remains divided between optimistic traders focusing on the company's AI growth cycle and skeptical bears citing profitability concerns and the impact of the new consumption-based pricing model.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following positive Phase 3 IZAR-1 trial results in psoriatic arthritis, though investor sentiment remains divided due to the data meeting endpoints without establishing a clear "best-in-class" advantage over existing therapies. While some traders express frustration with management and the stock's performance, others view the safety profile and upcoming catalysts—including an HS BLA submission—as drivers for long-term value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
